Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILAUDID vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dilaudid (hydromorphone) is a full opioid agonist with high affinity for mu-opioid receptors, producing analgesia by mimicking endogenous endorphins and enkephalins. It also activates kappa and delta opioid receptors to a lesser extent.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Management of moderate to severe pain in opioid-tolerant patients requiring an around-the-clock analgesic for an extended period,Off-label: acute pain management, preanesthetic medication, cough suppression
Relief of moderate to moderately severe pain
Initial: 2-4 mg orally every 4-6 hours as needed; or 1-2 mg intramuscularly, subcutaneously, or intravenously every 4-6 hours as needed.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
2.5-3.5 hours (terminal); prolonged in hepatic/renal impairment
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via glucuronidation; major metabolites: hydromorphone-3-glucuronide (H3G, active) and hydromorphone-6-glucuronide (H6G); minor pathways: N-demethylation to norhydromorphone; CYP450 involvement minimal.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Primarily renal (90% as hydromorphone-3-glucuronide and parent drug); <1% biliary/fecal
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
~20% (primarily albumin)
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
1.2-1.7 L/kg; indicates extensive tissue distribution
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Oral: 50-60% (first-pass); IM: ~100%; Rectal: ~50-60%
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
e GFR 30-60 m L/min: Administer 75% of usual dose; e GFR <30 m L/min: Administer 50% of usual dose; avoid in severe impairment.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
Child-Pugh class A: No adjustment; Child-Pugh class B: Reduce dose by 25-50%; Child-Pugh class C: Avoid use or reduce dose by 50-75%.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Children >12 years: 2-4 mg orally every 4-6 hours; 0.1-0.2 mg/kg intramuscularly/subcutaneously/intravenously every 4-6 hours (max single dose 4 mg).
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Initiate at 25-50% of adult dose; increase cautiously; monitor for respiratory depression, sedation, and constipation.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
Risk of respiratory depression, particularly in opioid-naive patients and those with respiratory compromise; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of fatal overdose when used with benzodiazepines or CNS depressants.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Respiratory depression (especially with concurrent CNS depressants); addiction potential; risk of opioid-induced hyperalgesia; severe hypotension; adrenal insufficiency; androgen deficiency; impairment of mental/physical abilities; risk of serotonin syndrome with serotonergic drugs; risk of severe hypotension in hypovolemic patients; caution in elderly, cachectic, or debilitated patients.
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Significant respiratory depression; acute or severe bronchial asthma (in unmonitored settings); known or suspected gastrointestinal obstruction (e.g., paralytic ileus); hypersensitivity to hydromorphone or any excipients; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days.
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Avoid grapefruit juice as it may increase hydromorphone levels via CYP3A4 inhibition. High-fat meals may delay absorption of immediate-release formulations but do not significantly alter overall exposure. Maintain adequate fluid and fiber intake to prevent constipation.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS). High doses near term may cause neonatal respiratory depression.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Hydromorphone is excreted into breast milk in low concentrations. M/P ratio approximately 0.8-1.0 (estimated). Relative infant dose <2% of maternal weight-adjusted dose. Monitor infant for sedation, respiratory depression, and withdrawal. Use with caution, especially in preterm or compromised infants.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
Pregnancy increases clearance and volume of distribution for hydromorphone; dose may need to be increased or given more frequently, especially in the third trimester. Titrate to effect while avoiding excessive sedation. Postpartum, clearance returns to prepregnancy levels; reduce dose accordingly.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
Dilaudid (hydromorphone) is 5–10 times more potent than morphine. Use with caution in opioid-naive patients; start at low doses. Avoid in patients with significant respiratory depression, paralytic ileus, or acute asthma. Monitor for signs of hypotension, especially in hypovolemic patients. May cause histamine release with pruritus, but less than morphine. For breakthrough pain, immediate-release oral solution provides fastest oral onset. Not recommended for chronic pain without careful reassessment. Reversal with naloxone, but short infusion may be needed due to longer duration.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Do not crush, chew, or break extended-release tablets; swallow whole.,Avoid alcohol and other CNS depressants (benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, coma, and death.,Do not drive or operate heavy machinery until you know how this medication affects you.,Store securely out of sight and reach of children; dispose of unused medication via take-back program or mixing with unpalatable substance and trashing.,Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Common side effects include drowsiness, dizziness, constipation, nausea, and vomiting. Laxatives and hydration may help constipation.,Seek emergency help if you have trouble breathing, slow heartbeat, severe dizziness, or fainting.,Tell all healthcare providers you are taking this medication before any surgery or procedure.,Do not stop suddenly without doctor guidance to avoid withdrawal symptoms (anxiety, sweating, diarrhea, muscle aches).
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILAUDID vs ANEXSIA, answered by our medical review team.
DILAUDID is a Opioid Analgesic that works by Dilaudid (hydromorphone) is a full opioid agonist with high affinity for mu-opioid receptors, producing analgesia by mimicking endogenous endorphins and enkephalins. It also activates kappa and delta opioid receptors to a lesser extent.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILAUDID and ANEXSIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILAUDID is: Initial: 2-4 mg orally every 4-6 hours as needed; or 1-2 mg intramuscularly, subcutaneously, or intravenously every 4-6 hours as needed.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILAUDID and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILAUDID is classified as Category C. First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal absti. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.